Clinical trial
A Study of the Safety and Effects of ADH-1 Given Daily to Subjects With Solid…
NCT00225550 · Adherex Technologies, Inc., Industry · Terminated
Key facts
| NCT number | NCT00225550 |
|---|---|
| Title | A Study of the Safety and Effects of ADH-1 Given Daily to Subjects With Solid Tumors |
| Official title | Dose Finding, Safety, Pharmacokinetic and Pharmacodynamic Study of the Vascular Targeting Agent Exherin™ (ADH-1) Administered Once Daily for 5 Consecutive Days by Intravenous Infusion in Subjects With N-Cadherin Expressing, Incurable, Solid Tumors (Adherex Protocol Number AHX 01 003) |
| Lead sponsor | Adherex Technologies, Inc., Industry |
| Status | Terminated |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Neoplasms |
| Intervention type | Drug |
| Interventions | ADH -1 (Exherin™) |
| First posted | Sep 26, 2005 |
| Last update posted | Aug 6, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: